Status:
RECRUITING
FearLess in NeuroOncology
Lead Sponsor:
Virginia Commonwealth University
Collaborating Sponsors:
National Cancer Institute (NCI)
National Brain Tumor Society
Conditions:
Primary Malignant Brain Tumor
Glioblastoma (GBM)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearL...
Detailed Description
The purpose of this study is to assess the feasibility, acceptability, appropriateness (FAA) of recruitment methods, study population, and waitlist design to finalize the protocol of FearLess, a psych...
Eligibility Criteria
Inclusion
- Patients:
- Self-report a diagnosis of a primary malignant brain tumor (grade II-IV)
- \>2 weeks post-cranial resection or biopsy
- Elevated Fear of Recurrence Distress Rating
- Primarily English speaking
- \>/= 18 years of age at the time of enrollment
- Caregivers:
- nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)
- Elevated Fear of Recurrence Distress Rating
- Primarily English speaking
- \>/= 18 years of age at the time of enrollment
Exclusion
- Patient / Caregiver Exclusion:
- Cognitive impairment that might prohibit active intervention engagement
- Inability to understand and provide informed consent
- Inability to attend virtual sessions due to unstable or no internet connection
Key Trial Info
Start Date :
June 24 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT06989086
Start Date
June 24 2025
End Date
December 31 2028
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298